DGAP-News: Nanostart-holding MagForce AG announces treatment of recurrent glioblastoma patient with NanoTherm therapy
(firmenpresse) - DGAP-News: Nanostart AG / Key word(s): Miscellaneous
Nanostart-holding MagForce AG announces treatment of recurrent
glioblastoma patient with NanoTherm therapy
10.10.2011 / 09:17
---------------------------------------------------------------------
- Patient treated at the University of Giessen and CharitéUniversity
Medical Center Berlin in an interdisciplinary cooperation
- The first treatment approvals have been received from German state
insurance companies
Frankfurt / Berlin, October 10, 2011 - Nanostart-holding
MagForce AG (FSE: MF6), a leading medical technology company focusing on
nanomedicine in oncology, announced today the treatment of a recurrent
glioblastoma patient with the company's NanoTherm(R) therapy. Based on an
individual patient agreement, the treatment costs are being covered by a
German state insurance company. The first part of the therapy (instillation
of the nanoparticles) was carried out at the University Giessen and
subsequent steps (nanoparticle activation and the accompanying
radiotherapy) were performed at the CharitéUniversity Medical Center
Berlin.
'We are pleased that treatment with NanoTherm therapy for brain tumors
patients has begun, and especially that treatment costs have been supported
by a number of state insurance companies through individual patient
agreements. This is a great milestone for both our novel technology and
for MagForce as a company,' said Dr. Peter Heinrich, CEO of MagForce.
'Through our collaborations with experts in both Germany and
internationally, we plan to further develop this treatment approach for a
variety of solid tumor indications with high medical need.'
Glioblastoma is the most common and most aggressive malignant primary brain
tumor in adults. Recurrent glioblastoma is the reoccurring growth
following treatment of the primary tumor.
About Nanostart:
Nanostart AG, headquartered in the German financial capital
of Frankfurt, is a leading nanotechnology investment company, with
portfolio companies spanning the globe from Silicon Valley to Singapore.
The company provides venture capital financing for nanotechnology companies
in various growth phases with a focus on innovation-driven industries of
the future such as cleantech, life sciences and IT/electronics. Through its
subsidiary Nanostart Asia (www.nanostart-asia.com) and the venture capital
fund in Singapore, Nanostart is proud to be the investment partner of the
Singaporean government. For further information, please visit
www.nanostart.de.
About MagForce:
MagForce AG is a leading medical technology company focusing on
nanomedicine in oncology. The company's proprietary procedure, NanoTherm(R)
therapy, enables the targeted treatment of solid tumors through the
intratumoral generation of heat via activation of magnetic nanoparticles.
NanoTherm(R), NanoPlan(R), and NanoActivator(TM) are components of the
therapy and have received EU-wide regulatory approval as medical devices
for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan and
NanoActivator are trademarks of MagForce AG in selected countries.
About NanoTherm(R) therapy:
NanoTherm(R) therapy involves the direct injection of magnetic
nanoparticles into the tumor and their subsequent heating by an alternating
magnetic field. The water-soluble nanoparticles are approximately 15
nanometers in diameter and contain an iron oxide core with an aminosaline
coating, which causes the particles to agglomerate following injection. The
particles are then activated by a magnetic field that changes its polarity
100,000 times per second, and heat is produced within the tumor. Depending
on the temperature reached and length of treatment, the tumor cells are
either directly destroyed or sensitized for the accompanying chemotherapy
or radiation.
Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of
offers to purchase or subscribe to securities. There will be no public
offering of securities of Nanostart AG in conjunction with the existing
listing of its shares in the 'Entry Standard' segment of the regulated
unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This
notice does not constitute a securities prospectus. Neither this notice nor
the information contained within is intended for direct or indirect
distribution within Canada, Australia or Japan.
Media contact:
Nanostart AG
Dr. Hans Joachim Duerr
Head of Corporate Communications
Goethestrasse 26-28
D-60313 Frankfurt, Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 150
e-mail: presse(at)nanostart.de
End of Corporate News
---------------------------------------------------------------------
10.10.2011 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
141744 10.10.2011
Themen in dieser Pressemitteilung:
nanostart
holding-magforce-ag-announces-treatment-of-recurrent-glioblastoma-patient-with-nanotherm-therapy
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: EquityStory
" alt="Alexandria Minerals Corporation Announces $3,000,000 FinancingDatum: 10.10.2011 - 09:17 Uhr
Sprache: Deutsch
News-ID 74092
Anzahl Zeichen: 4132
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 235 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Nanostart-holding MagForce AG announces treatment of recurrent glioblastoma patient with NanoTherm therapy"
steht unter der journalistisch-redaktionellen Verantwortung von
Nanostart AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
